about
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunityEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityInvestigating Evolutionary Conservation of Dendritic Cell Subset Identity and FunctionsDendritic cell-based vaccination in cancer: therapeutic implications emerging from murine modelsMolecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of CancerFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeA Pan-Cancer Catalogue of Cancer Driver Protein Interaction InterfacesActivation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancerTumor Interstitial Fluid Formation, Characterization, and Clinical ImplicationsImmunity, inflammation, and cancer: an eternal fight between good and evil.Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients.STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysMechanisms of transcriptional activation of the stimulator of interferon genes by transcription factors CREB and c-Myc.Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis.Immunotherapy and tumor microenvironmentCheckpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.Regulation of prostate cancer progression by the tumor microenvironment.Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.MYC regulates the antitumor immune response through CD47 and PD-L1Immune checkpoint dysfunction in large and medium vessel vasculitis.Innate immune mediators in cancer: between defense and resistance.Endoplasmic reticulum proteostasis: a key checkpoint in cancer.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Type I Interferons and Natural Killer Cell Regulation in Cancer.Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.Immune Diseases Associated with TREX1 and STING Dysfunction.STING-mediated DNA sensing in cancer immunotherapy.Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity.An RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway.
P2860
Q26782131-0B15BC26-E85C-4869-8DCB-D25BEFDDD785Q26796313-41B99D7F-647C-4842-8BAC-AAFA34E6E61AQ26995456-7739E1EA-1625-4B1A-945E-4BE9C8EB5C50Q27012618-308155B5-46B7-4E17-8BB8-BB6D1517BE58Q28080773-428C9A85-E687-4B9B-B1DF-BB0E61F2ED56Q28119095-9FDA0FAD-724A-41CE-BBF6-21E6A4E66BEAQ28550391-581656B1-15CA-43FF-8515-45D4F5FD65D7Q33718199-6D3CE23A-CF80-44DE-97D1-EB75F816B150Q33815894-90951F43-17CE-44E0-9406-244FBE96CE7BQ35646453-FE0084DA-C557-44A2-A478-C59F1A57F623Q36106053-56673029-1D9E-47CB-A554-5DDC48CCF368Q36583710-9C2575D9-484B-4D4B-A51E-474B3115D966Q36821232-D4185CB4-3B38-4747-B76D-C393C3FC5FBFQ36939977-243F166F-FF99-4138-90CA-E9C6DE88D153Q37222197-45A3F701-BED0-4C9B-BA74-62BB20195D81Q37257918-176D926D-289B-43D4-A6F9-BA6011444425Q37315492-5316D381-1A3A-40C3-BE78-EFB2A783A8ADQ37502464-D6970AAE-86BF-4FFE-8874-BC8CCAE1494CQ37545824-20D5EDA1-5DC5-4509-8E03-7EF8583EC29CQ37554718-68A05682-239D-4913-ACB2-5766ABEB27F6Q37688869-84E3B641-6E0C-4C0E-8FFA-167E95F4F75FQ37690959-36F565D4-11B7-488C-8632-60CDB6F8AC07Q37709077-536186AF-4C0E-4DA2-8EB4-C59202946482Q38431732-1AE587BF-FCC0-457D-971B-84A87950D64CQ38610306-F12EEB9C-B63D-4EBF-8715-D03E70C05547Q38654099-9648BA42-6E1E-4DCC-A4EA-612E6A9E34BDQ38717262-45055831-9295-4CCF-A762-3DFC73672063Q38757931-AC6B97CD-ABEC-484D-BCA5-E5D709B63172Q38787131-C5331086-798A-4B53-8188-63B23556C247Q38897019-4BC592C5-3B10-4550-8E14-11F5F14C9991Q38991015-E512E1F4-B9A5-4864-975C-CF73F8FD169DQ39011260-ECF28495-F9CA-4F45-B62E-3D45072D88F7Q39069273-9564C251-0DDD-422C-A84B-92B99139473DQ39241784-77E678C4-46FB-46FE-82D4-975B0DEF5107Q39281091-B61CDF34-15EF-4B2B-A5A9-937EE5E67B60Q39285868-7B3D1B51-A54E-410F-9FDC-034BEC8D9820Q39389951-4F8E84ED-D4AD-4C9A-B9FE-D616F0CFF52DQ39427382-6E34A831-F84A-450C-BEDD-158C7365E1F8Q40163840-B180E9A3-430A-4E57-85B8-6D36BD28FF81Q40434927-28EB528F-4F7B-448B-A251-40FA07F4489A
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Innate immune recognition of cancer.
@ast
Innate immune recognition of cancer.
@en
type
label
Innate immune recognition of cancer.
@ast
Innate immune recognition of cancer.
@en
prefLabel
Innate immune recognition of cancer.
@ast
Innate immune recognition of cancer.
@en
P2093
P1476
Innate immune recognition of cancer.
@en
P2093
Leticia Corrales
Seng-Ryong Woo
Thomas F Gajewski
P304
P356
10.1146/ANNUREV-IMMUNOL-032414-112043
P577
2015-01-22T00:00:00Z